2,370 reports of this reaction
2.0% of all LEVETIRACETAM IN SODIUM CHLORIDE reports
#8 most reported adverse reaction
FATIGUE is the #8 most commonly reported adverse reaction for LEVETIRACETAM IN SODIUM CHLORIDE, manufactured by Actavis Pharma, Inc.. There are 2,370 FDA adverse event reports linking LEVETIRACETAM IN SODIUM CHLORIDE to FATIGUE. This represents approximately 2.0% of all 117,343 adverse event reports for this drug.
Patients taking LEVETIRACETAM IN SODIUM CHLORIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for LEVETIRACETAM IN SODIUM CHLORIDE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for LEVETIRACETAM IN SODIUM CHLORIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,370 FDA reports for LEVETIRACETAM IN SODIUM CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.0% of all adverse event reports for LEVETIRACETAM IN SODIUM CHLORIDE, making it a notable side effect.
If you experience fatigue while taking LEVETIRACETAM IN SODIUM CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.